{
    "version": "1.0",
    "provider_name": "BioPark",
    "provider_url": "https:\/\/biopark.ee\/en",
    "author_name": "Mariann N\u00f5lvak",
    "author_url": "https:\/\/biopark.ee\/en\/author\/mariann\/",
    "title": "Tartu firma arendab koos \u00fclikooliga nutikat v\u00e4hiteraapiat - BioPark",
    "type": "rich",
    "width": 600,
    "height": 338,
    "html": "<blockquote class=\"wp-embedded-content\" data-secret=\"5IPRQzOfR6\"><a href=\"https:\/\/biopark.ee\/en\/uudised\/tartu-firma-arendab-koos-ulikooliga-nutikat-vahiteraapiat\/\">Tartu firma arendab koos \u00fclikooliga nutikat v\u00e4hiteraapiat<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/biopark.ee\/en\/uudised\/tartu-firma-arendab-koos-ulikooliga-nutikat-vahiteraapiat\/embed\/#?secret=5IPRQzOfR6\" width=\"600\" height=\"338\" title=\"&#8220;Tartu firma arendab koos \u00fclikooliga nutikat v\u00e4hiteraapiat&#8221; &#8212; BioPark\" data-secret=\"5IPRQzOfR6\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/* ]]> *\/\n<\/script>",
    "description": "Ravimitootjate maailmas k\u00e4ib suur v\u00f5idujooks nutika, t\u00e4pselt suunatud ning patsiendile v\u00f5imalikult leebe v\u00e4hiteraapia arendamiseks. Tartu Biotehnoloogia Pargi inkubatsiooniettev\u00f5te ToxInvent annab oma panuse innovatiivsete ravimikandidaatide protot\u00fc\u00fcpide loomiseks. Selleks tehakse enam kui 600 000 eurose eelarvega rakendusuuring koost\u00f6\u00f6s Tartu \u00dclikooli bio- ja siirdemeditsiini instituudiga. L\u00e4hemalt r\u00e4\u00e4gib ettev\u00f5tte teadus- ja arendustegevusest ToxInvent O\u00dc juhatuse liige Andrus Tasa. Kuidas [&hellip;]"
}